Visit
IMS 2022
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?
Check out our interview with @MosqueraOrgeira below:
👉http://ow.ly/zJYI50MzXgg👈
@ASH_hematology #ASH22 #MPNsm #HemOnc #AI
🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?
Check out our interview with @MosqueraOrgeira below:
👉http://ow.ly/zJYI50MzXgg👈
@ASH_hematology #ASH22 #MPNsm #HemOnc #AI
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?
IMS 2022
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?
Check out our interview with @MosqueraOrgeira below:
👉http://ow.ly/zJYI50MzXgg👈
@ASH_hematology #ASH22 #MPNsm #HemOnc #AI
🚨 Want to learn more about the application of AI and machine learning in myelofibrosis prognostication?
Check out our interview with @MosqueraOrgeira below:
👉http://ow.ly/zJYI50MzXgg👈
@ASH_hematology #ASH22 #MPNsm #HemOnc #AI
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
